SEC Form 6-K filed by SOPHiA GENETICS SA
Form 20-F | x | Form 40-F |
SOPHiA GENETICS SA | |||||||||||
Date: | May 6, 2025 | ||||||||||
By: | /s/ Daan van Well | ||||||||||
Name: | Daan van Well | ||||||||||
Title: | Chief Legal and Compliance Officer |
Exhibit No. | Description | ||||
Form 20-F | x | Form 40-F |
SOPHiA GENETICS SA | |||||||||||
Date: | May 6, 2025 | ||||||||||
By: | /s/ Daan van Well | ||||||||||
Name: | Daan van Well | ||||||||||
Title: | Chief Legal and Compliance Officer |
Exhibit No. | Description | ||||
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/18/2024 | $11.00 | Buy | Craig Hallum |
8/7/2024 | $10.00 → $5.00 | Overweight → Equal-Weight | Morgan Stanley |
6/27/2024 | $6.00 | Buy | Guggenheim |
11/29/2023 | $8.00 | Outperform | RBC Capital Mkts |
7/5/2023 | $10.00 | Overweight | JP Morgan |
1/3/2023 | $6.00 | Buy | BTIG Research |
11/23/2022 | $2.00 | Neutral | Credit Suisse |
2/15/2022 | $23.00 → $18.00 | Overweight | Morgan Stanley |
BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basisGross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectivelyIFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign excha
BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (NASDAQ:AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024, this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025. Developed in collaboration with Memorial Sloan Kettering Cancer Cen
BOSTON and ROLLE, Switzerland, April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be